Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in T2D - Pablo F. Mora, MD, FACE, CDE
Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? Expert- and Trial-Based Evidence for the Safety and Efficacy of Long-Acting Basal Insulin.
Related Presenters
Dallas Diabetes Research Center at Medical City Dallas (Texas)Adjunct Associate Professor University of Texas Southwestern Medical Center at Dallas (Texas)